| scholarly article | Q13442814 |
| P50 | author | Michael Weller | Q2779469 |
| P2093 | author name string | Patrick Roth | |
| Antonios Valavanis | |||
| P2860 | cites work | Prospects of immune checkpoint modulators in the treatment of glioblastoma | Q28081371 |
| Immunotherapy response assessment in neuro-oncology: a report of the RANO working group | Q28083009 | ||
| Immunotherapy for glioblastoma: concepts and challenges | Q38592188 | ||
| P433 | issue | 3 | |
| P921 | main subject | glioblastoma | Q282142 |
| P304 | page(s) | 454-456 | |
| P577 | publication date | 2017-03-01 | |
| P1433 | published in | Neuro-Oncology | Q15724471 |
| P1476 | title | Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab | |
| P478 | volume | 19 |
| Q64267591 | Clinical chimeric antigen receptor-T cell therapy: a new and promising treatment modality for glioblastoma |
| Q57486475 | Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time |
| Q50422388 | Effect of Gamma Knife Radiosurgery and Programmed Cell Death 1 Receptor Antagonists on Metastatic Melanoma |
| Q62491509 | Emerging Applications of Artificial Intelligence in Neuro-Oncology |
| Q89767107 | Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas |
| Q47849021 | PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions |
| Q45999303 | Prospective feasibility trial for genomics-informed treatment in recurrent and progressive glioblastoma. |
| Q92881504 | Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma |
| Q47126110 | Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas |
| Q61449923 | The Prognostic and Therapeutic Value of PD-L1 in Glioma |
Search more.